Gilead’s Kite gains some height after second CAR-T approval ...

Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T

Gilead closes in on second CAR-T approval in US

EMA starts review of second CAR-T from Gilead’s Kite unit

Gilead to file new CAR-T, setting up potential mid-2020 laun...

Gilead’s Kite unit plans to file its latest CAR-T therapy on the basis of a new study showing some impressive response rates in patients with relapsed or refractory mantle cell lymphoma.

Calquence approval another win for AstraZeneca in oncology

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL).

Janssen's Imbruvica runs into trouble with NICE in mantle ce...

NICE suggests interim CDF funding while further data is gathered.